BioTech

Somaxon, The Ten-Bagger Chase (SOMX, SNY)

BioTech Investor - BioTech Stock News - 18 March 2010 - 1:45pm
There is a new weapon in the war on insomnia, and one which does not appear to have the drug dependence and the nasty side-effects associated with many other sleep aids.  Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) announced this morning that the FDA has approved the New Drug Application for Silenor as a treatment of insomnia [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Teva Could Be Seeking Mega-Cap Status (TEVA, PFE, NVS, MRK, SNY)

BioTech Investor - BioTech Stock News - 18 March 2010 - 10:28am
Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is slowly becoming one of the biggest drug makers in the world.  This morning the company is up on the news that it won the bidding process to acquire German generic drug maker Ratiopharm GmbH.  The price tag: 3.6 billion Euros, or about $5 billion today in a cash [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Abraxis Looks Promising in Lung Cancer War (ABII)

BioTech Investor - BioTech Stock News - 17 March 2010 - 9:49am
Abraxis BioScience, Inc. (NASDAQ: ABII) is one of the top biotech gainers this morning.  The company announced that its key ABRAXANE met the primary endpoint in a Phase 3 trial for advanced non-small cell lung cancer. The company’s randomized Phase 3 clinical trial comparing ABRAXANE, the company’s protein-bound paclitaxel, along with with a Taxol injection, in [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

StemCells Scores New Stem Cell Patent (STEM)

BioTech Investor - BioTech Stock News - 17 March 2010 - 9:29am
StemCells, Inc. (NASDAQ: STEM) has a new stem cell patent.  For rats, issued in the United Kingdom.  The company issued a release showing that the United Kingdom Intellectual Property Office granted patent number GB2451523. The patent has broad claims covering true rat stem cells and genetically engineered rats derived from these cells, which is expected to [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Stem Cells Versus Aging, Fountain of Youth (BTIM, GERN, ACTC)

BioTech Investor - BioTech Stock News - 16 March 2010 - 12:58pm
How many movies and legends are based upon eternal youth?  Hundreds or thousands for sure.  BioTime, Inc. (NYSE Amex: BTIM) is seeing a massive surge of interest today after the company announced a “Peer-Reviewed Scientific Publication on the Reversal of the Developmental Aging of Normal Human Cells.” The company is a small-cap biotechnology company (approximately $250 [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Sequenom Still Seeks Down’s Syndrome Grail (SQNM)

BioTech Investor - BioTech Stock News - 15 March 2010 - 4:29pm
Sequenom, Inc. (NASDAQ: SQNM) is trading lower in the after-hours session after the troubled diagnostics company reported its year-end earnings.  Because of its recent woes of 2009, the earnings and revenue reports are a true side-show compared to what the company is updating over its pipeline and over its products. We would note that actual trading [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

OSI Can’t Stay Indpendent Forever (OSIP)

BioTech Investor - BioTech Stock News - 15 March 2010 - 2:55pm
OSI Pharmaceuticals Inc. (NASDAQ: OSIP) is holding up yet again, despite the notion that Astellas Pharma, Inc. of Japan wants to acquire the company.  OSI decided to formally reject the $52.00 per share tender offer and is recommending that its shareholders reject the offer while it contacts other parties.  Today we have a counter-response from [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Savient, Gout, and FDA… Back At The Door (SVNT)

BioTech Investor - BioTech Stock News - 15 March 2010 - 10:07am
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) is from giving up on its KRYSTEXXA as a gout treatment.  This morning the company announced that it has resubmitted its Biologics License Application to the FDA.  This has been in the news, particularly since the company announced a secondary offering late last year after the FDA denied this in [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

High Hopes on Ariad (ARIA, MRK)

BioTech Investor - BioTech Stock News - 10 March 2010 - 4:02pm
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) is seeing elevated trading today after a presentation and ahead of earnings. The difference here is that Ariad’s increased trading is in both the stock and in the bonds. Joe Kunkle of OptionsHawk.com noted, “implied volatility is 10% higher to 87.8% as shares gain 2.7%, 4,140 calls trading, [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

More Drug and BioHealth Dividends (MRX, WCRX, AMGN, MRK, PFE, PPH, BBH)

BioTech Investor - BioTech Stock News - 10 March 2010 - 11:08am
Medicis (NYSE: MRX), a specialty pharmaceutical company in treatments of dermatological and aesthetic conditions, has the talk going again about dividends in the drug and biotech sector.  The company declared a quarter-end cash quarterly dividend of $0.06 payable on April 30, 2010 for holders of record at the close of business on April 1, 2010.  [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

The Facet Biotech Buyout Saga (FACT, BIIB, ABT, PDLI)

BioTech Investor - BioTech Stock News - 10 March 2010 - 9:30am
Facet Biotech Corporation (NASDAQ: FACT) is a buyout saga that seemed as though it would never end in 2009.  The company is now finally being acquired, but not by Biogen Idec (NASDAQ: BIIB).  Abbott Laboratories (NYSE: ABT) announced last night that it entered into a definitive agreement for $27.00 per share in a cash buyout.  [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

EDAP TMS, Back on the Map (EDAP)

BioTech Investor - BioTech Stock News - 9 March 2010 - 2:20pm
EDAP TMS SA (NASDAQ: EDAP) is a French company which makes medical devices for the treatment of urological diseases and the company’s stock is soaring after the company was granted marketing approval of its newly designed, high-end Sonolith I-Sys lithotripsy device by the Japanese Administration.  Because this market is still under-served, we wanted to look [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Amylin & Friends Brace for Diabetes Review (AMLN, LLY, ALKS)

BioTech Investor - BioTech Stock News - 8 March 2010 - 3:44pm
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) has a big event on deck this week.  This Friday, March 12, is its Prescription Drug User Fee Act (PDUFA) action date for an FDA panel to issue a recommendation on Byetta as the the first once a week treatment for Type II diabetes.  The date had been moved due [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

The Changing Landscape of Biotech Valuations (ACOR, CBST, MNKD, INCY, SGEN, ITMN, IPXL, MRX, SVNT, VPHM)

BioTech Investor - BioTech Stock News - 6 March 2010 - 4:12pm
The biotech and biohealth universe is changing in size.  In 2008 and 2009, partly due to mergers and partly due to market valuations, there had become a surprisingly small number of biotech stocks which had market capitalization rates of more than $1 billion.  At one point there were only about 10 or 11 in our [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

When Biotech Layoffs Come (XNPT)

BioTech Investor - BioTech Stock News - 5 March 2010 - 3:34pm
When conglomerates and consumer products lay off workers and employees, shareholders generally cheer the company for saving money and cutting costs by figuring out productivity measures that milk more output per employee.  That leaves more income and ultimately brings more dividends down the road.  But biotech firms are far from being thought of in the [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Winning from Boosting Good Cholesterol (RVXCF, RVX, PFE, AZN, MRK)

BioTech Investor - BioTech Stock News - 5 March 2010 - 12:13pm
BioHealthInvestor usually sticks to US companies or at least sticks to ADRs for investors.  But sometimes there is a much larger bit of data either north of the border or in Europe.  There is a company called  Resverlogix Corp. which trades in Canada under the ticker ‘RVX’ and the stock also trades in the US [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Talking Biotech ETFs: iShares Nasdaq Biochnology to $100 (IBB, OSIP, MDVN)

BioTech Investor - BioTech Stock News - 3 March 2010 - 4:49pm
Today’s price moves in the biotech sector are quite different from what we saw earlier this week.  A hostile merger via tender from Astellas for OSI Pharmaceuticals Inc. (NASDAQ: OSIP) got everyone up in arms this week.  So much that other investors were going back over buyout candidate notes.  We also gave a list of [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Biotech Implosion: Medivation, Alzheimer’s Beats Drug (MDVN, PFE)

BioTech Investor - BioTech Stock News - 3 March 2010 - 9:36am
Medivation, Inc. (NASDAQ: MDVN) is the next biotech implosion.  The company’s highly awaited Phase III study on its Alzheimer drug called Dimebon did not meet expectations. It failed to meet primary and secondary endpoints. The problem is that this was hitting 52-week highs yesterday. The company did note that a separate Phase 3 safety study demonstrated [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

More Biotech Buyout or M&A Targets (OSIP, VRTX, AUXL, ITMN, HGSI, CELG, DNDN, ENZN, FACT, PBE, XBI)

BioTech Investor - BioTech Stock News - 1 March 2010 - 2:06pm
After today’s hostile Astellas offer for OSI Pharmaceuticals (NASDAQ: OSIP), we have investors and traders alike looking for ‘the next takeover target’ in biotech.  Buy now you know that there are many pitfalls in simply looking for biotech stocks to buy because they will be taken over.  We have taken a look through our own [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Hostile Mergers Back in Biotech (OSIP)

BioTech Investor - BioTech Stock News - 1 March 2010 - 9:20am
Mergers are back in biotech…. Astellas Pharma Inc., a global pharmaceutical company in Japan, announced that it will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals (NASDAQ: OSIP).  The direct tender is nothing short of a hostile merger after Astellas said that OSI has refused to discuss terms. The [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

WPS Video Board

Most played videos

Most downloaded

Top videos

Latest image

QASP testing resistance!

Random video

Latest videos

We allll pick stocks. Trade quick DD and tell everybody whats getting sexy tomorrow.

Syndicate content